Key result
Ex vivo treatment with AGI-1067 significantly inhibited ADP-induced platelet aggregation and decreased surface expression of major platelet receptors.
Why the study?
Does ex vivo AGI-1067 inhibit platelet aggregation and surface receptor expression in blood from aspirin-naïve volunteers with vascular risk factors?
Does ex vivo AGI-1067 inhibit platelet aggregation and surface receptor expression in blood from aspirin-naïve volunteers with vascular risk factors?
The novel antioxidant AGI-1067 demonstrates significant ex vivo antiplatelet activity by inhibiting ADP-induced aggregation and key surface receptors, suggesting potential as a therapeutic agent.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for AGI-1067 antiplatelet effects; prospective trials needed before any clinical consideration.
Oxidation-sensitive signals are important in platelet activation. The novel, phenolic, intracellular and extra-cellular antioxidant AGI-1067 inhibits the expression of a number of proinflammatory genes involved in atherosclerosis. The effect of AGI-1067 on human platelets was evaluated. Blood obtained from 20 aspirin-naïve volunteers with multiple risk factors for vascular disease was preincubated with escalating concentrations of AGI-1067 for the assessment of its ex vivo effects on platelet aggregation and expression of major surface receptors flow cytometry, evaluated by flow cytometry. AGI-1067 resulted in significant inhibition of a variety of activation-dependent platelet biomarkers in healthy volunteers, including adenosine diphosphate-induced platelet aggregation and decreased surface platelet expression of glycoprotein IIb/IIIa antigen, activity with PAC-1 antibody, and glycoprotein Ib (CD42b). The effect of AGI-1067 differs from other known antiplatelet agents, suggesting opportunities for therapeutic combination. These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant.
No takes yet. Share an insight, caveat, or question.
Serebruany et al. (2006) studied Multiple risk factors for vascular disease (n=20). AGI-1067 was evaluated on Platelet aggregation and expression of major surface receptors. Ex vivo treatment with AGI-1067 significantly inhibited ADP-induced platelet aggregation and decreased surface expression of major platelet receptors.
Synapse has enriched 10 related papers. Consider them for comparative context: